International – Orphan drugs face “uphill battle” in 2020

A new analysis from GlobalData has claimed that the number of orphan drug designations (ODD) being handed out by both the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) is declining.

The company has revealed that over the last six years, the numbers have slowed down despite the visible benefits of such designations in speeding these drugs through development and to patients.

Quentin Horgan, pharma analyst at the firm explains that the EMA had a “much greater” decline in unique drugs awarded ODDs than the FDA – with the EU-based organisation showing a 49% decrease between 2014 and 2019, while the FDA only had an 8% decrease across the same time period…